{
    "path": [
        907040000,
        802000000
    ],
    "contexts": [
        " with a provision of the law, details are included in the endnotes. Introduction  (1) This Order sets out what kinds of information are required to be included on the label of medicines of the kind described in section 3, and in what circumstances. (2) The purpose of the label on a medicine is to provide information about the medicine such as its identity, potency, content, storage, expiry date, dose, directions for use, sponsor details and registration\/listing status. Labels on medicines can al",
        " which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active ingredient, if: (iii) this is in a text size of not less than 3.0 millimetres; and "
    ]
}
{
    "path": [
        908030000,
        907000000
    ],
    "contexts": [
        "s in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label.  (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then:  (a) where the medicine contains three or fewer active ingredients, the name of the active ingredient(s) and the quantity or proportion of active ingredient(s) must be displayed on the main label in a",
        "c) (i) the total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; a"
    ]
}
{
    "path": [
        802060000,
        802050000
    ],
    "contexts": [
        "an the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or ",
        "about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.  (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background.  (3) If the medicine is registered goods and  (a) both: (i) the medicine is a medicated throat lozenge or an inor"
    ]
}
{
    "path": [
        907030000,
        901030000
    ],
    "contexts": [
        "ents specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the quantity of the medicine; and  (f) the batch number of the medicine preceded by the batch number prefix; and  (g) the expiry date of the medicine, preceded by the ",
        " active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or h"
    ]
}
{
    "path": [
        1009020000,
        900000000
    ],
    "contexts": [
        "of the medicine.  (5) If the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under subsection 8(1) must be applied on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include:  (a) the name of the medicine; and  (b) the n",
        "be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the medicine preceded by the expiry date "
    ]
}
{
    "path": [
        1005000000,
        900000000
    ],
    "contexts": [
        "of the medicine.  (5) If the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under subsection 8(1) must be applied on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include:  (a) the name of the medicine; and  (b) the n",
        "e that are not, such as by including the statement \u2018contains homoeopathic preparations of\u2019 adjacent to the list of homoeopathic ingredients, or by prefacing the name of the homoeopathic active ingredient with the term \u2018homoeopathic\u2019.  (5) Sunscreen preparations If:  (a) the medicine is a sunscreen preparation; and  (b) is enclosed in a container with a capacity of not more than 25 millilitres, then, in relation to compliance with sections 8 and 9, it shall be sufficient if (i) the sun protectio"
    ]
}
{
    "path": [
        907020000,
        802000000
    ],
    "contexts": [
        " with a provision of the law, details are included in the endnotes. Introduction  (1) This Order sets out what kinds of information are required to be included on the label of medicines of the kind described in section 3, and in what circumstances. (2) The purpose of the label on a medicine is to provide information about the medicine such as its identity, potency, content, storage, expiry date, dose, directions for use, sponsor details and registration\/listing status. Labels on medicines can al",
        "in subparagraphs 9(7)(a)(i) and (ii) do not apply to the main label on the primary pack;  (b) where the medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) app"
    ]
}
{
    "path": [
        601150000,
        801030000
    ],
    "contexts": [
        "described in paragraph 42AA(1)(c) of the Act; \"composite pack\" has the same meaning as in the Act; \"container\" has the same meaning as in the Act; \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer; \"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (",
        "ents specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the quantity of the medicine; and  (f) the batch number of the medicine preceded by the batch number prefix; and  (g) the expiry date of the medicine, preceded by the "
    ]
}
{
    "path": [
        1102070000,
        1102060000
    ],
    "contexts": [
        "ngredient released in a stated time;  (f) for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient is: (i) the quantity delivered per actuation; or where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation;  (g) for preparations applied to the",
        "active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation;  (g) for preparations applied to the skin and mucous membranes, other than those covered by paragraph (f) - as a percentage expressed in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate;  (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients in"
    ]
}
{
    "path": [
        805000000,
        801000000
    ],
    "contexts": [
        "ed or debossed and not printed; and  (f) unless otherwise specified elsewhere in this Order, be in metric units of measurement.  8 Information to be included on the label  (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medici",
        "; and  (f) the name of the sponsor or distributor, or a registered trademark if it readily identifies the sponsor or distributor of the medicine.  (5) If the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under subsection 8(1) must be applied on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section"
    ]
}
{
    "path": [
        1008030000,
        900000000
    ],
    "contexts": [
        "of the medicine.  (5) If the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under subsection 8(1) must be applied on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include:  (a) the name of the medicine; and  (b) the n",
        " 8 and 9, it shall be sufficient if the name of the medicine is displayed.  (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.  (9) Strip, blister and dial dispenser packs  (a) Subject to paragraph (b)"
    ]
}
{
    "path": [
        905030000,
        901030000
    ],
    "contexts": [
        "ents specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the quantity of the medicine; and  (f) the batch number of the medicine preceded by the batch number prefix; and  (g) the expiry date of the medicine, preceded by the ",
        "rear panel or rear label instead of on the main label; and  (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.  (6) If the medicine is intended to be, or is, listed good"
    ]
}
{
    "path": [
        1009010000,
        900000000
    ],
    "contexts": [
        "of the medicine.  (5) If the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under subsection 8(1) must be applied on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include:  (a) the name of the medicine; and  (b) the n",
        "nits can only be extracted individually; and (iii) the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active in"
    ]
}
{
    "path": [
        1001000000,
        1007000000
    ],
    "contexts": [
        "oved Names List for medicine released for supply on or after 1 May 2028.  10 Qualifications and special requirements  (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include:  (a) the name of any antimicrobial preservative in the medicine;  (b) if the medicine, other than an ophthalmic oint",
        "et out on the label consistent with the requirements specified in the Regulations. Note: The label on the container and on the primary pack (if any) of each medicine within a medicine kit must comply with the requirements of this Order.  (7) Small containers If:  (a) the medicine is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the lab"
    ]
}
{
    "path": [
        905030000,
        802000000
    ],
    "contexts": [
        " with a provision of the law, details are included in the endnotes. Introduction  (1) This Order sets out what kinds of information are required to be included on the label of medicines of the kind described in section 3, and in what circumstances. (2) The purpose of the label on a medicine is to provide information about the medicine such as its identity, potency, content, storage, expiry date, dose, directions for use, sponsor details and registration\/listing status. Labels on medicines can al",
        "rear panel or rear label instead of on the main label; and  (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.  (6) If the medicine is intended to be, or is, listed good"
    ]
}
{
    "path": [
        907030000,
        901020000
    ],
    "contexts": [
        "e included on the label  (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the quantity of the medicine; and  (f) the batch number of the medicine preceded by the batch n",
        " active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or h"
    ]
}
{
    "path": [
        1007000000,
        1001000000
    ],
    "contexts": [
        "oved Names List for medicine released for supply on or after 1 May 2028.  10 Qualifications and special requirements  (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include:  (a) the name of any antimicrobial preservative in the medicine;  (b) if the medicine, other than an ophthalmic oint",
        "et out on the label consistent with the requirements specified in the Regulations. Note: The label on the container and on the primary pack (if any) of each medicine within a medicine kit must comply with the requirements of this Order.  (7) Small containers If:  (a) the medicine is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the lab"
    ]
}
{
    "path": [
        1009010000,
        800000000
    ],
    "contexts": [
        "expiry date prefix; and (ii) the batch number and batch number prefix when that information is embossed or debossed and not printed; and  (f) unless otherwise specified elsewhere in this Order, be in metric units of measurement.  8 Information to be included on the label  (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ing",
        "nits can only be extracted individually; and (iii) the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active in"
    ]
}
{
    "path": [
        910020000,
        911000000
    ],
    "contexts": [
        "n, must be displayed in a text size of not less than 2.5 millimetres.  (10) Subsection 9(9) does not apply:  (a) where the medicine is supplied in a small container; or  (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or  (c) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2\u2014after 30 April 2028. Note: The",
        "ve ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in this Order.  (11) An active ingredient specified in Part 1 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026.  (12) To avoid doubt, an active ingredient specified in Part 1 of Schedule 2 must be included on the main label "
    ]
}
{
    "path": [
        907030000,
        802000000
    ],
    "contexts": [
        " with a provision of the law, details are included in the endnotes. Introduction  (1) This Order sets out what kinds of information are required to be included on the label of medicines of the kind described in section 3, and in what circumstances. (2) The purpose of the label on a medicine is to provide information about the medicine such as its identity, potency, content, storage, expiry date, dose, directions for use, sponsor details and registration\/listing status. Labels on medicines can al",
        " active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or  (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or  (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or h"
    ]
}
{
    "path": [
        903020000,
        1102090000
    ],
    "contexts": [
        "ne might be disrupted or obscured, adjacent to the name of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium containe",
        " is a herbal preparation, as the dry or fresh weight of the herbal material from which the preparation was derived except: (A) where standardisation of the herbal preparation is claimed on the label, then, the minimum dry or fresh weight of herbal material from which the preparation is derived and the quantity of standardised constituents(s) in the herbal preparation; or (B) where the active ingredient is a herbal preparation that is an essential oil; (iii) where the active ingredient is an enzy"
    ]
}
{
    "path": [
        1102080000,
        1102040000
    ],
    "contexts": [
        "or (B) in the case where the medicine is one of a series of strengths containing the same active ingredient - as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume; and Example: Where the dose volume is 5 mL after preparati",
        "ated weight or volume of the medicine, as appropriate;  (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.  (i) In addition to the requirements of paragraphs 11("
    ]
}
{
    "path": [
        1008030000,
        800000000
    ],
    "contexts": [
        "expiry date prefix; and (ii) the batch number and batch number prefix when that information is embossed or debossed and not printed; and  (f) unless otherwise specified elsewhere in this Order, be in metric units of measurement.  8 Information to be included on the label  (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ing",
        " 8 and 9, it shall be sufficient if the name of the medicine is displayed.  (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.  (9) Strip, blister and dial dispenser packs  (a) Subject to paragraph (b)"
    ]
}
{
    "path": [
        1102080000,
        1102020000
    ],
    "contexts": [
        "an active ingredient to be included on a label must be expressed:  (a) for a discrete dosage unit - as the quantity of the active ingredient in the dosage unit;  (b) for a solid for ingestion, where there is no discrete dosage unit - as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid;  (c) subject to paragraph (d) below, if the medicine is a liquid for ingestion: (i) as the quantity of the active ingredient contained in the stated volume of a",
        "ated weight or volume of the medicine, as appropriate;  (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.  (i) In addition to the requirements of paragraphs 11("
    ]
}
{
    "path": [
        802050000,
        802030000
    ],
    "contexts": [
        "and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.  (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.  (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (suc",
        "an the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or "
    ]
}
{
    "path": [
        910030000,
        913000000
    ],
    "contexts": [
        "s labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or  (c) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2\u2014after 30 April 2028. Note: The minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in this Order.  (11) An active ingredient specified in Part 1 of Schedule 2, either alone or in combination wi",
        "t in accordance with the Australian Approved Names List for medicine released for supply on or after 1 May 2026.  (13) An active ingredient specified in Part 2 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2028.  (14) To avoid doubt, an active ingredient specified in Part 2 of Schedule 2 must be included on the main label "
    ]
}
{
    "path": [
        908030000,
        906020000
    ],
    "contexts": [
        "ve ingredient, and the name of the dosage form, may appear on a side panel or side label or on a rear panel or rear label; or  (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label.  (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then:  (a) where the medicine co",
        "c) (i) the total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; a"
    ]
}
{
    "path": [
        302020000,
        500000000
    ],
    "contexts": [
        "ption and related medicines. (2) To avoid doubt, this Order will apply to the following medicines: (a) medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations and (b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order. 4 Transition arrangements  (1) On and from 31 August 2016 and before 1 September 2020, each medicine to which this Order applies must comply with either: (a) the requirements specified in",
        "nufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). 5 Exemptions \u2013 Medicines to which this Order does not apply   This Order does not apply to a medicine that is: (a) intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act; or (b) intended to be supplied to a Cate"
    ]
}
{
    "path": [
        802050000,
        802040000
    ],
    "contexts": [
        "rpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.  (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution, additional warning or advisory statements).  (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be includ",
        "an the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or "
    ]
}
{
    "path": [
        403000000,
        402000000
    ],
    "contexts": [
        "nes (TGO 69), up until 30 June 2017 (inclusive); or (ii) Therapeutic Goods Order No. 69 - General Requirements for Labels for Medicines 2017 (TGO 69 (2017)), on or after 1 July 2017. (2) On and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order. (3) Notwithstanding (1) and (2), medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must com",
        "r 2020, each medicine to which this Order applies must comply with the requirements specified in this Order. (3) Notwithstanding (1) and (2), medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). 5 Exemptions \u2013 Medicines to which this Order does not apply   This Order does not apply to a medicine that i"
    ]
}
{
    "path": [
        301000000,
        500000000
    ],
    "contexts": [
        "Order No. 92 - Standard for labels of non-prescription medicines. 3 Application - Therapeutic goods to which this Order applies (1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines. (2) To avoid doubt, this Order will apply to the following medicines: (a) medicines of a kind specified in Parts 2 and 3 of Sch",
        "nufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). 5 Exemptions \u2013 Medicines to which this Order does not apply   This Order does not apply to a medicine that is: (a) intended for use in the treatment of another person in accordance with an approval set out in paragraph 19(1)(a) of the Act; or (b) intended to be supplied to a Cate"
    ]
}
{
    "path": [
        1102080000,
        1102030000
    ],
    "contexts": [
        " active ingredient contained in the stated volume of a suitable dose of the liquid; or (ii) in the case where the liquid for ingestion is one of a series of strengths containing the same active ingredient \u2013 as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. Example: Where the dose volume is 5 mL, and there are",
        "ated weight or volume of the medicine, as appropriate;  (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.  (i) In addition to the requirements of paragraphs 11("
    ]
}
{
    "path": [
        903020000,
        1102080000
    ],
    "contexts": [
        "ne might be disrupted or obscured, adjacent to the name of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium containe",
        "ated weight or volume of the medicine, as appropriate;  (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.  (i) In addition to the requirements of paragraphs 11("
    ]
}
{
    "path": [
        802030000,
        802020000
    ],
    "contexts": [
        "where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.  (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the",
        "and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.  (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.  (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (suc"
    ]
}
{
    "path": [
        601150000,
        801100000
    ],
    "contexts": [
        "described in paragraph 42AA(1)(c) of the Act; \"composite pack\" has the same meaning as in the Act; \"container\" has the same meaning as in the Act; \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer; \"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (",
        "cine; (ii) the circumstances as set out in Column 2 of Schedule 1 exist in relation to such a substance or no circumstances are set out in Column 2; and (iii) the medicine is intended to be administered via any one or more of the route(s) of administration referred to in Column 3 of Schedule 1, then: (iv) a statement: (A) indicating that the medicine contains the substance expressed using the Name stated in Column 4 of Schedule 1; and (B) where any of the circumstances and requirements set out "
    ]
}
{
    "path": [
        910000000,
        909000000
    ],
    "contexts": [
        "in the composite pack or medicine kit.  (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres.  (10) Subsection 9(9) does not apply: ",
        "r, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres.  (10) Subsection 9(9) does not apply:  (a) where the medicine is supplied in a small container; or  (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or  (c) wh"
    ]
}
{
    "path": [
        1009020000,
        800000000
    ],
    "contexts": [
        "expiry date prefix; and (ii) the batch number and batch number prefix when that information is embossed or debossed and not printed; and  (f) unless otherwise specified elsewhere in this Order, be in metric units of measurement.  8 Information to be included on the label  (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ing",
        "be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the medicine preceded by the expiry date "
    ]
}
{
    "path": [
        908040000,
        906020000
    ],
    "contexts": [
        "ve ingredient, and the name of the dosage form, may appear on a side panel or side label or on a rear panel or rear label; or  (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label.  (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then:  (a) where the medicine co",
        " paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and  (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.  (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient nam"
    ]
}
{
    "path": [
        1103030000,
        1103020000
    ],
    "contexts": [
        "edient, homoeopathic medicine and it is clear that the ingredient comprises 100% of the medicine \u2013 the name of the active ingredient; or  (b) where all active ingredients of the medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contains equal parts of ...\u2019 followed by the name of each active ingredient; or  (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine  (4) Pe",
        " medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contains equal parts of ...\u2019 followed by the name of each active ingredient; or  (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine  (4) Permitted statements of storage temperature conditions For the purposes of this Order, the following statements of storage temperature conditions are permitted: (i) \u2018Store below \u20131"
    ]
}
{
    "path": [
        903020000,
        1105000000
    ],
    "contexts": [
        "ne might be disrupted or obscured, adjacent to the name of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium containe",
        "orage temperature conditions as specified in the approved product details in relation to the medicine.  (5) Inclusion of common names of vitamins Where a medicine contains an active ingredient that is a vitamin, then the word \u2018vitamin\u2019, or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin, may appear on a main label of the medicine either:  (a) on the same line of text - between the approved name of the active ingredient that is a vitamin a"
    ]
}
{
    "path": [
        1007000000,
        900000000
    ],
    "contexts": [
        "of the medicine.  (5) If the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under subsection 8(1) must be applied on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include:  (a) the name of the medicine; and  (b) the n",
        "et out on the label consistent with the requirements specified in the Regulations. Note: The label on the container and on the primary pack (if any) of each medicine within a medicine kit must comply with the requirements of this Order.  (7) Small containers If:  (a) the medicine is enclosed in a small container; and  (b) the container is enclosed in a primary pack, the label of which complies with sections 8 and 9 and subsection 10(1) (if applicable), then, in relation to compliance of the lab"
    ]
}
{
    "path": [
        301000000,
        400000000
    ],
    "contexts": [
        "Order No. 92 - Standard for labels of non-prescription medicines. 3 Application - Therapeutic goods to which this Order applies (1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines. (2) To avoid doubt, this Order will apply to the following medicines: (a) medicines of a kind specified in Parts 2 and 3 of Sch",
        "he following medicines: (a) medicines of a kind specified in Parts 2 and 3 of Schedule 10 to the Regulations and (b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order. 4 Transition arrangements  (1) On and from 31 August 2016 and before 1 September 2020, each medicine to which this Order applies must comply with either: (a) the requirements specified in this Order; or (b) the requirements specified in: (i) Therapeutic Goods Ord"
    ]
}
{
    "path": [
        1008020000,
        900000000
    ],
    "contexts": [
        "of the medicine.  (5) If the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under subsection 8(1) must be applied on the delivery device and not the container.  9 Information to be included on the main label  (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include:  (a) the name of the medicine; and  (b) the n",
        " sponsor or distributor of the medicine.  (b) If: (i) the medicine consists only of pastilles or lozenges; and (ii) each dosage unit is enclosed in an unsealed individual wrapper; and (iii) each dosage unit is, after being so wrapped, enclosed in a primary pack that complies with sections 8 and 9, then, in relation to compliance of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.  (c) Where: (i) a medicine consists of d"
    ]
}
{
    "path": [
        1005000000,
        800000000
    ],
    "contexts": [
        "expiry date prefix; and (ii) the batch number and batch number prefix when that information is embossed or debossed and not printed; and  (f) unless otherwise specified elsewhere in this Order, be in metric units of measurement.  8 Information to be included on the label  (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ing",
        "e that are not, such as by including the statement \u2018contains homoeopathic preparations of\u2019 adjacent to the list of homoeopathic ingredients, or by prefacing the name of the homoeopathic active ingredient with the term \u2018homoeopathic\u2019.  (5) Sunscreen preparations If:  (a) the medicine is a sunscreen preparation; and  (b) is enclosed in a container with a capacity of not more than 25 millilitres, then, in relation to compliance with sections 8 and 9, it shall be sufficient if (i) the sun protectio"
    ]
}
{
    "path": [
        601150000,
        801020000
    ],
    "contexts": [
        "described in paragraph 42AA(1)(c) of the Act; \"composite pack\" has the same meaning as in the Act; \"container\" has the same meaning as in the Act; \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer; \"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (",
        "e included on the label  (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include:  (a) the name of the medicine; and  (b) the name(s) of all active ingredients in the medicine; and  (c) the quantity or proportion of all active ingredients in the medicine; and  (d) the name of the dosage form; and  (e) the quantity of the medicine; and  (f) the batch number of the medicine preceded by the batch n"
    ]
}
{
    "path": [
        903030000,
        903010000
    ],
    "contexts": [
        "aph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must:  (a) appear as a cohesive unit by the placing of the name and quantity of each active ingredient together on separate lines of text either (i) immediately below the name of the medicine; or (ii) where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine; and  (b) not be separated by any text or graphics, except where additional information is: (i) requir",
        "fferent formulations of the medicines contained in a composite pack or a medicine kit;  (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.  (4) All text required by this Order to be on the main label must be oriented in the s"
    ]
}
{
    "path": [
        1103030000,
        1103010000
    ],
    "contexts": [
        "ts for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include:  (a) where the medicine is a fully potentised, single ingredient, homoeopathic medicine and it is clear that the ingredient comprises 100% of the medicine \u2013 the name of the active ingredient; or  (b) where all active ingredients of the medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contai",
        " medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contains equal parts of ...\u2019 followed by the name of each active ingredient; or  (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine  (4) Permitted statements of storage temperature conditions For the purposes of this Order, the following statements of storage temperature conditions are permitted: (i) \u2018Store below \u20131"
    ]
}
{
    "path": [
        601150000,
        801120000
    ],
    "contexts": [
        "described in paragraph 42AA(1)(c) of the Act; \"composite pack\" has the same meaning as in the Act; \"container\" has the same meaning as in the Act; \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer; \"delivered dose\" means, in relation to: (a) metered dose preparations - the dose delivered to the patient in a single actuation or delivery; and (",
        " determined for each individual patient by a health professional authorised under a law of a State or Territory to determine the dose; or (ii) there is insufficient space on the label of either the container or the primary pack, or both, to include directions for use, and: (A) those directions for use are set out in a package insert provided in the primary pack of the medicine; and (B) a statement is included on whichever label on the container, or the primary pack, or both, that does not set ou"
    ]
}
{
    "path": [
        802050000,
        802020000
    ],
    "contexts": [
        "where the medicine is registered goods, the critical health information must be displayed on the label of the primary pack in a tabulated form.  (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information.  (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the",
        "an the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or "
    ]
}
{
    "path": [
        908040000,
        907000000
    ],
    "contexts": [
        "s in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label.  (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then:  (a) where the medicine contains three or fewer active ingredients, the name of the active ingredient(s) and the quantity or proportion of active ingredient(s) must be displayed on the main label in a",
        " paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and  (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.  (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient nam"
    ]
}